

## Select molecule

**Bimekizumab**  
(Anti-IL-17A and IL-17F)

**Certolizumab Pegol**  
(Anti-TNF)

**Rozanolixizumab**  
(Anti-FcRn)

**Dapirolizumab Pegol**  
(CD40 Ligand Antibody)

---

# UCB IMMUNOLOGY CLINICAL DEVELOPMENT PROGRAMME

---

**The right molecule, to the right  
patient, for the right indication**

The information presented is correct as of September 2020. All information is based upon, and is available via, the [clinicaltrials.gov](https://clinicaltrials.gov) website.

GL-N-OT--2000071

Date of preparation: October 2020



Inspired by **patients.**  
Driven by **science.**

**Bimekizumab**  
(Anti-IL-17A and IL-17F)

**Certolizumab Pegol**  
(Anti-TNF)

**Rozanolixizumab**  
(Anti-FcRn)

**Dapirolizumab Pegol**  
(CD40 Ligand Antibody)

Trial	NCT Number	Phase	2017	2018	2019	2020	2021	2022	2023	2024	2025
<b>Moderate-to-Severe Chronic Plaque Psoriasis (PSO)</b>											
BE VIVID: H2H: Efficacy and Safety of Bimekizumab vs Ustekinumab in PSO <sup>1</sup>	NCT03370133	3		██████████							
BE READY: Efficacy and Safety of Bimekizumab in PSO with a randomized withdrawal period <sup>2</sup>	NCT03410992	3		██████████							
BE SURE: H2H: Efficacy and Safety of Bimekizumab vs Adalimumab in PSO <sup>3</sup>	NCT03412747	3		██████████							
BE RADIANT: H2H: Efficacy and Safety of Bimekizumab vs Secukinumab in PSO <sup>4</sup>	NCT03536884	3		██████████	██████████						
BE BRIGHT: Long-Term Safety, Tolerability and Efficacy of Bimekizumab in PSO <sup>5</sup>	NCT03598790	3		██████████	██████████	██████████					
Safety and Effective Use of PFS or AI for Self-Injection of Bimekizumab in PSO <sup>6</sup>	NCT03766685	3			██████████						
<b>Axial Spondyloarthritis (axSpA)</b>											
Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Active AS <sup>7</sup>	NCT03215277	2		██████████							
Long-Term Safety and Efficacy of Bimekizumab in AS <sup>8</sup>	NCT03355573	2		██████████	██████████	██████████					
BE MOBILE 1: Efficacy and Safety of Bimekizumab in Active Non-radiographic axSpA <sup>9</sup>	NCT03928704	3			██████████	██████████					
BE MOBILE 2: Efficacy and Safety of Bimekizumab in Active AS <sup>10</sup>	NCT03928743	3			██████████	██████████					
BE MOVING: Long-Term Safety, Tolerability and Efficacy of Bimekizumab in Active axSpA, Including AS and Non-radiographic axSpA <sup>11</sup>	NCT04436640	3				██████████	██████████	██████████			
<b>Psoriatic Arthritis (PsA)</b>											
Long-Term Safety and Efficacy of Bimekizumab in PsA <sup>12</sup>	NCT03347110	2		██████████							
BE OPTIMAL: Efficacy and Safety of Bimekizumab in Active PsA <sup>13</sup>	NCT03895203	3			██████████	██████████					
BE COMPLETE: Efficacy and Safety of Bimekizumab in Active PsA <sup>14</sup>	NCT03896581	3			██████████						
BE VITAL: Long-term Safety, Tolerability and Efficacy of Bimekizumab in Active PsA <sup>15</sup>	NCT04009499	3			██████████	██████████	██████████	██████████			
Safe and Effective Use of PFS or AI for Self-Injection of Bimekizumab in Active PsA <sup>16</sup>	NCT04109976	3			██████████						

AI: Auto-injector, AS: ankylosing spondylitis, H2H: Head-to-head, PFS: Pre-filled syringe.

**IMPORTANT NOTE:** Bimekizumab is currently in clinical development and is not approved in the EU or by any Health Authorities.

References

**Bimekizumab**  
(Anti-IL-17A and IL-17F)

**Certolizumab Pegol**  
(Anti-TNF)

**Rozanolixizumab**  
(Anti-FcRn)

**Dapirolizumab Pegol**  
(CD40 Ligand Antibody)

Trial	NCT Number	Phase	2017	2018	2019	2020	2021	2022	2023	2024
Moderate-to-Severe Hidradenitis Suppurativa (HS)										
BE HEARD 1: Efficacy and Safety of Bimekizumab in HS <sup>17</sup>	NCT04242446	3								
BE HEARD 2: Efficacy and Safety of Bimekizumab in HS <sup>18</sup>	NCT04242498	3								

References

Bimekizumab  
(Anti-IL-17A and IL-17F)

**Certolizumab Pegol**  
(Anti-TNF)

Rozanolixizumab  
(Anti-FcRn)

Dapirolizumab Pegol  
(CD40 Ligand Antibody)

Trial	NCT Number	Phase	2017	2018	2019	2020	2021	2022	2023	2023	2025								
Moderate-to-Severe Chronic Plaque Psoriasis (PSO)																			
CIMREAL: Assess Certolizumab Pegol in PSO as Part of Routine Clinical Practice <sup>19</sup>	NCT04053881	NS																	
CIMcare: Efficacy, Safety, and Drug Concentration of Certolizumab Pegol in Children and Adolescent Patients with PSO <sup>20</sup>	NCT04123795	3																	
Trial	NCT Number	Phase	2015	2016	2017	2018	2019	2020	2021	2022									
Axial Spondyloarthritis (axSpA)																			
C-Optimise: Investigating Dose Regimens of Certolizumab Pegol for Maintenance of Sustained Remission in Active axSpA <sup>21</sup>	NCT02505542	3																	
C-axSpAnd: Efficacy and Safety of Certolizumab Pegol in Active axSpA Without X-ray Evidence of Ankylosing Spondylitis (AS) <sup>22</sup>	NCT02552212	3																	
Trial	NCT Number	Phase	2017	2018	2019	2020	2021	2022	2023	2024									
Specific Populations																			
CHERISH: Assess exposure of Certolizumab Pegol in Pregnant Women with Chronic Inflammatory Diseases <sup>23</sup>	NCT04163016	1																	
Trial	NCT Number	Phase	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Crohn's Disease (CD)																			
SECURE: Certolizumab Pegol CD Post-Marketing Registry <sup>24</sup>	NCT00844285	NS																	

NS, Non-probability sample.

**IMPORTANT NOTE:** Certolizumab pegol is not currently approved in CD, and is not indicated in children and adolescents, in the EU. Certolizumab pegol should only be used during pregnancy when there is a clinical need.

References

**Bimekizumab**  
(Anti-IL-17A and IL-17F)

**Certolizumab Pegol**  
(Anti-TNF)

**Rozanolixizumab**  
(Anti-FcRn)

**Dapirolizumab Pegol**  
(CD40 Ligand Antibody)

Trial	NCT Number	Phase	2015	2016	2017	2018	2019	2020	2021	2022
<b>Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</b>										
My CIDP choice: Safety, Tolerability and Efficacy of Rozanolixizumab in CIDP <sup>25</sup>	NCT03861481	2					██████████			
Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in CIDP <sup>26</sup>	NCT04051944	2					██████████	██████████		
<b>Myasthenia Gravis (MG)</b>										
Safety, Tolerability and Efficacy of Rozanolixizumab in Moderate-to-Severe MG <sup>27</sup>	NCT03052751	2			██████████					
Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalised MG <sup>28</sup>	NCT03971422	3					██████████	██████████		
<b>Immune Thrombocytopenia (IT)</b>										
Safety, Tolerability and Efficacy of Rozanolixizumab in Primary IT <sup>29</sup>	NCT02718716	2		██████████	██████████					
myOpportunITy1: Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients with Persistent or Chronic Primary IT <sup>30</sup>	NCT04200456	3						██████████	██████████	
myOpportunITy2: Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients with Persistent or Chronic Primary IT <sup>31</sup>	NCT04224688	3						██████████	██████████	

[References](#)

**IMPORTANT NOTE:** Rozanolixizumab pegol is currently in clinical development and is not approved in the EU or by any Health Authorities.

**Bimekizumab**  
(Anti-IL-17A and IL-17F)

**Certolizumab Pegol**  
(Anti-TNF)

**Rozanolixizumab**  
(Anti-FcRn)

**Dapirolizumab Pegol**  
(CD40 Ligand Antibody)

Trial*	NCT Number	Phase	2015	2016	2017	2018	2019	2020	2021	2022
Systemic Lupus Erythematosus (SLE)										
Efficacy and Safety Study of Dapirolizumab Pegol in SLE <sup>32</sup>	NCT02804763	2		█						
Efficacy and Safety Study of Dapirolizumab Pegol in Moderately-to-Severely Active SLE <sup>33</sup>	NCT04294667	3							█	

\*In Collaboration with Biogen.

**IMPORTANT NOTE:** Dapirolizumab Pegol is currently in clinical development and is not approved in the EU or by any Health Authorities.

References

**Bimekizumab**  
(Anti-IL-17A and IL-17F)

**Certolizumab Pegol**  
(Anti-TNF)

**Rozanolixizumab**  
(Anti-FcRn)

**Dapirolizumab Pegol**  
(CD40 Ligand Antibody)

## References

1. NCT03370133 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03370133>. Accessed 06/09/2020.
2. NCT03410992 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03410992>. Accessed 06/09/2020.
3. NCT03412747 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03412747>. Accessed 06/09/2020.
4. NCT03536884 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03536884>. Accessed 06/09/2020.
5. NCT03598790 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03598790>. Accessed 06/09/2020.
6. NCT03766685 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03766685>. Accessed 06/09/2020.
7. NCT03215277 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03215277>. Accessed 06/09/2020.
8. NCT03355573 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03355573>. Accessed 06/09/2020.
9. NCT03928704 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03928704>. Accessed 06/09/2020.
10. NCT03928743 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03928743>. Accessed 06/09/2020.
11. NCT04436640 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04436640>. Accessed 06/09/2020.
12. NCT03347110 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03347110>. Accessed 06/09/2020.
13. NCT03895203 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03895203>. Accessed 06/09/2020.
14. NCT03896581 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03896581>. Accessed 06/09/2020.
15. NCT04009499 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04009499>. Accessed 06/09/2020.
16. NCT04109976 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04109976>. Accessed 06/09/2020.
17. NCT04242446 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04242446>. Accessed 06/09/2020.
18. NCT04242498 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04242498>. Accessed 06/09/2020.
19. NCT04053881 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04053881>. Accessed 06/09/2020.
20. NCT04123795 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04123795>. Accessed 06/09/2020.
21. NCT02505542 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT02505542>. Accessed 06/09/2020.
22. NCT02552212 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT02552212>. Accessed 06/09/2020.
23. NCT04163016 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04163016>. Accessed 06/09/2020.
24. NCT00844285 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT00844285>. Accessed 06/09/2020.
25. NCT03861481 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03861481>. Accessed 06/09/2020.
26. NCT04051944 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04051944>. Accessed 06/09/2020.
27. NCT03052751 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03052751>. Accessed 06/09/2020.
28. NCT03971422 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT03971422>. Accessed 06/09/2020.
29. NCT02718716 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT02718716>. Accessed 06/09/2020.
30. NCT04200456 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04200456>. Accessed 06/09/2020.
31. NCT04224688 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04224688>. Accessed 06/09/2020.
32. NCT02804763 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT02804763>. Accessed 06/09/2020.
33. NCT04294667 Clinical Study Record. <https://clinicaltrials.gov/ct2/show/NCT04294667>. Accessed 06/09/2020.